Stockwinners Market Radar for August 10, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:58 EDT Adverum Biotechnologies' ADVM-022 trial yields positive results in cohorts 1-4 - Adverum Biotechnologies announced positive new interim data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration, or AMD. For the first time, interim data from all four cohorts of the OPTIC trial including preliminary safety data from Cohort 4, are presented. These data further demonstrate the "transformative potential of ADVM-022" to greatly reduce the treatment burden for patients with wet AMD.

19:17 EDT Activision Blizzard's Macartney sells nearly 13,000 shares - In a regulatory filing, Activision Blizzard chief people officer Claudine Macartney disclosed the sale of 12,902 common shares of the company on August 6 at a price of $86.0605 per share.

18:50 EDT MVC Capital to merge into Barings BDC - Barings BDC (BBDC) and MVC Capital (MVC) have entered into a definitive merger agreement under which MVC Capital will merge with and into Barings BDC. The combined company, which will remain externally managed by Barings LLC, is expected to have more than $1.2B of investments on a pro forma basis. The transaction is expected to close in Q4. Under the merger agreement, MVC Capital stockholders will receive aggregate consideration of approximately $177.5M in the form of cash and stock consideration representing total book value consideration of $10.01 per fully diluted MVC Capital share. The transaction represents total consideration for MVC Capital stockholders of $145.5M or approximately $8.21 per share, representing a premium of 21% to MVC Capital's closing price on August 10. MVC Capital stockholders will receive 0.94024 Barings BDC shares for each MVC Capital share, resulting in approximately 16.7 million newly issued Barings BDC shares, having total value of $170.5M, or $9.62 per share. In addition, Barings LLC will pay approximately $7M in cash, or $0.39492 per share, directly to MVC Capital stockholders at closing. Following the Transaction, Barings BDC's equity base is expected to expand by $170M and Barings BDC stockholders and MVC Capital stockholders are expected to own approximately 74.2% and 25.8%, respectively, of the combined company. Barings BDC has agreed that, on the closing date, it will increase the size of its board of directors and cause one current member of the board of directors of MVC Capital, to be mutually selected by MVC Capital and Barings BDC to be appointed to the Barings BDC board of directors. MVC Capital will repay all outstanding amounts under its existing credit facilities and any remaining obligations thereunder will be terminated. In addition, in connection with the closing of the proposed Transaction, Barings BDC intends to redeem MVC Capital's 6.25% senior notes due November 30, 2022 with an aggregate principal amount outstanding of $95.0M. Barings BDC estimates NII per share to be 18c-20c in the first full quarter post-closing vs. 14c per share during Q2. Consummation of the transaction is subject to Barings BDC and MVC Capital stockholder approval, customary regulatory approvals and other closing conditions.

18:41 EDT Support.com appoints Lance Rosenzweig as CEO - Support.com has elected Lance Rosenzweig to succeed Rick Bloom as President and CEO as of August 10. Rick will step down as CEO following four years with the company. To ensure a seamless transition, Rick will continue as Support.com's Principal Financial Officer for the next few months and will remain an active member of the company's Board of Directors. Lance Rosenzweig has served as CEO of Startek, Aegis USA, and PeopleSupport, which he co-founded.

18:08 EDT GreenSky up over 10% at $7.00 per share after Q2 earnings beat

17:41 EDT Ligand to acquire Pfenex for $12 per share or $516M - Ligand Pharmaceuticals (NLGND) and Pfenex (PFNX) announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438M in equity value on a fully diluted basis. In addition, Ligand will pay $2.00 per share or $78 million as a Contingent Value Right in the event a predefined regulatory milestone is achieved by December 31, 2021, for a total transaction value of up to $516 million. The closing of this transaction is subject to customary conditions and is expected to occur in the fourth quarter. Ligand will provide a detailed outlook for the Pfenex business and financial contribution after the transaction has closed. At this time, Ligand expects the transaction will be modestly dilutive to 2020 adjusted diluted EPS, will provide 10c-30c of adjusted diluted EPS accretion in 2021, and will provide significant annual adjusted diluted EPS accretion thereafter with the current forecast of 60c-80c in 2022 and $1.25 to $1.50 in 2023.

17:29 EDT General Dynamics awarded $428.23M Army contract - General Dynamics was awarded a $428.23M cost-plus-fixed-fee contract for the field level maintenance, field service representative support, contingency maintenance support, new equipment training and total package fielding for the family of Stryker vehicles. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of July 31, 2025. U.S. Army Contracting Command is the contracting activity.

17:14 EDT Hertz drops 7.7% after Q2 results

17:09 EDT Genasys acquires enterprise software provider, Amika Mobile - Genasys announced that it has entered into a definitive agreement under which Genasys would acquire Amika Mobile, a Canada-based enterprise software provider of critical event situational awareness, communication and control products. Combining our technology and product offerings and leveraging Amika Mobile's customer base and the synergies of our engineering teams better positions Genasys to fully address and successfully compete in several large vertical markets," stated Richard S. Danforth, Chief Executive Officer of Genasys Inc. "The combined suite of critical communications capabilities is expected to accelerate our software business growth. Our enhanced platform empowers companies, governments, communities, educational and medical institutions to improve safety and security for employees, residents, students and staff, and alleviate potential threats from pandemics, severe weather, natural disasters and other crisis situations." Amika Mobile's technology enables information sharing, rapid 2-way communications across devices and networks, and control through advanced integrations with government agency alerts and physical security systems. The Amika Mobility Server is designed to initiate individual, group or en masse, any layer alerts, and manage simultaneous responses for VoIP, SMS, Pop-ups, web, overhead displays, digital signs, Twitter and tickers, based on any automations, including government agency or weather alerting feeds, panic buttons or sensor events from digital thermometers, access control, fire panels, camera systems and more.

16:53 EDT j2 Global up 14% after Q2 earnings beat at $68.50 per share

16:49 EDT Bed Bath & Beyond says July comps were positive - In a regulatory 8-K filing, the company states: "In late May 2020, the Company started reopening stores to the public and, as of the end of July 2020, substantially all stores have re-opened. As previously disclosed in an Investor FAQs document furnished by the Company on a Current Report on Form 8-K filed on July 14, 2020, total net sales were down only 7% for the month of June, including more than an 80% increase in sales from digital channels and an approximately 25% decline in sales from stores, when, on average, there were 22% fewer store open days. For the month of June, total comparable sales, for stores that have reopened and from digital channels combined, was positive. Further, cash flow was positive in June. For the month of July, total net sales grew 2% over the prior year period, including more than a 70% increase in sales from digital channels and an approximately 15% decline in sales from stores. Total comparable sales for the month of July was positive. Cash flow continued to be positive in July."

16:48 EDT Sinclair Broadcast settles three derivative lawsuits - Sinclair Broadcast has agreed to settle three derivative lawsuits filed alleging breaches of fiduciary duties by the company's officers and directors in connection with Sinclair's efforts to seek regulatory approval of the merger with Tribune Media and the Hearing Designation Order issued by the Federal Communications Commission on July 19, 2018. On July 20, the parties to these lawsuits executed a settlement stipulation reflecting the terms of the settlement. Sinclair's board agreed to implement a series of corporate governance measures; defendants' insurers will pay $20.5M into a settlement fund, which will be paid to Sinclair; the board will designate an aggregate amount of $5M of the settlement fund to be used, over a period of five years, for the implementation and operation of the corporate governance measures and certain compliance programs in connection with an FCC consent decree announced on May 6; and Sinclair's Executive Chairman David Smith will forgo, cancel, or return a grant of SARs of 638,298 shares of Sinclair Class A common stock that was awarded to him in February. The corporate governance measures include, among other actions, the establishment of a Regulatory Committee to oversee responsibility for, among other matters, significant broadcast-related regulatory and compliance issues. In addition, Sinclair agreed to establish a standing Nominating and Governance Committee of the board and will appoint an experienced Chief Compliance Officer with enhanced responsibilities. The corporate governance measures also include the adoption of certain corporate governance guidelines and changes to Sinclair's Code of Business Conduct and Ethics policy and to the company's policies concerning related-party transactions. In exchange, and subject to final court approval, the lawsuits will be dismissed and defendants will be released of any claims relating to the Tribune merger or the HDO. The Court will consider whether to enter an order providing final approval to the settlement at a hearing currently scheduled for October 27.

16:40 EDT ICU Medical enters long-term U.S. distribution pact with Grifols - ICU Medical (ICUI) announced that it has entered into a long-term agreement with Grifols (GRFS) to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the United States. This new agreement will expand ICU Medical's non-PVC/non-DEHP offering to include 50 mL to 1000 mL container sizes. In addition, ICU Medical plans to distribute Grifols' Dextrose IV solutions when those products have received regulatory clearance for sale in the United States.

16:39 EDT Expedia's Battle acquires 12,300 common shares - In a regulatory filing, Expedia director A. George Battle disclosed the acquisition of 12,300 common shares of the company on August 7 at a price of $81.3828 per share.

16:37 EDT NetEase Cloud Music, Universal Music Group enter license agreement for China - NetEase Cloud Music and Universal Music Group announced a multi-year licensing agreement. Under the agreement, NetEase Cloud Music will directly distribute UMG's music, including domestic and international recording artists, on its streaming NetEase Cloud Music platform and associated digital services in China. NetEase Cloud Music subscribers will be able to access music on demand from UMG's full roster of artists, catalog, distributed labels - which together represent the most comprehensive collection of recordings, covering all musical genres. NetEase Cloud Music and UMG will also work together to create innovative campaigns and initiatives that will allow music fans in China to engage with both domestic artists from China and UMG's international talent from around the world. The agreement will also increase the scope of premium offerings and experiences available to music fans in China via NetEase Cloud Music.

16:32 EDT Bed Bath & Beyond lifts suspension of planned debt reductions - Bed Bath & Beyond announced that, in light of current business and market conditions, it has lifted the suspension of planned debt reductions, which had been implemented in response to the economic and market conditions resulting from the COVID-19 pandemic. The company also announced today that it has commenced cash tender offers to purchase up to $300M aggregate principal amount of its senior notes.

16:28 EDT Extended Stay America sees Q3 system-wide RevPAR (21%)-(18%)

16:27 EDT Cohen & Steers reports preliminary AUM $70.1B as of July 31 - An increase of $3.8B from assets under management at June 30.

16:22 EDT HTG Molecular in commercialization, distribution pact with Qiagen - HTG Molecular Diagnostics (HTGM) announced the signing of a Commercialization and Distribution Agreementwith QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN (QGEN). The 10-year agreement provides a foundation for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies global development, distribution and commercialization capabilities for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG's novel RNA platform. The Master Agreement allows HTG to engage directly with biopharma customers for CDx development programs including assay development, clinical trial oversight and global regulatory submissions, with potential CDx assays developed leveraging either an Illumina, Inc. or a Thermo Fisher Scientific NGS platform. In the event a CDx assay is required, the agreement provides HTG's customers global distribution and commercialization options with QIAGEN, a proven world-class molecular diagnostics leader. "Our biopharma customers want the ability to develop new biomarkers with our HTG EdgeSeq technology, along with the ability to distribute them globally. This new agreement is designed to allow them to do just that," said Byron Lawson, Senior Vice President and Chief Commercial Officer. "Ultimately, we can now provide our customers with the confidence that they will be able to use our HTG EdgeSeq technology and capabilities, while leveraging the proven commercial expertise and distribution scale of QIAGEN." John Lubniewski, President and Chief Executive Officer, added, "This new agreement preserves the original value we saw when we initially collaborated with QIAGEN in 2016; HTG EdgeSeq technology, leveraging either an Illumina or Thermo Fisher Scientific sequencer, with global commercialization and distribution options offered by QIAGEN, one of the largest molecular diagnostic companies in the industry. We are extremely pleased we were able to renew our partnership with QIAGEN and look forward to contracting new CDx programs to deliver on our mission to advance precision medicine."

16:21 EDT IFF authorizes 3% increase to dividend to 77c per share - On August 10, the Board of Directors of IFF authorized a 3%, or 2c increase, in the quarterly dividend to 77c per share of the Company's common stock. The quarterly dividend is payable on October 5 to shareholders of record as of September 24.

16:19 EDT Simon Property says all U.S. retail properties reopened as of July 10 - The company stated, "On March 18, 2020, after extensive discussions with federal, state and local officials and in recognition of the need to address the spread of COVID-19, the Company closed all of its retail properties in the United States. Our properties reopened, when permitted to do so under applicable governmental orders, beginning May 1. All of the Company's retail properties were reopened as of July 10. Seven retail properties in California were subsequently closed on July 15, and remain closed, due to a new restrictive governmental order. The Company's retail properties were closed, in aggregate, for approximately 10,500 shopping days during the second quarter. As of August 7, 91% of the tenants across the Company's U.S. retail properties were open and operating. More than half of the remaining unopened tenants are closed because of restrictive governmental orders limiting or prohibiting their operations. The Company has collected from its U.S. retail portfolio, including some level of rent deferrals, approximately 51% of its contractual rent billed for April and May combined, approximately 69% for June and approximately 73% for July with only de minimis deferrals. These percentages have not been adjusted for any rent abatements granted."

16:16 EDT Element Solutions acquires DMP Corporation, launches MacDermid Envio Solutions - Element Solutions announced its acquisition of DMP Corporation, a provider of turnkey wastewater treatment and recycle and reuse solutions across multiple manufacturing industries. The Company today also announced the formation of MacDermid Envio Solutions, a new business focused on helping customers profitably reduce their environmental impact through proprietary water treatment and metals recycling solutions. This business will report under Element Solutions' Industrial Solutions vertical but sell across ESI's broader end markets. Chief Executive Officer Benjamin Gliklich said, "As environmental concerns and regulation continue to drive change within the specialty chemicals industry and our existing supply chain, we continue to invest in technology to help our customers meet and exceed these requirements. The acquisition of DMP and formation of MacDermid Envio Solutions allow Element Solutions to offer its customers capabilities that are both needed today and will be needed more over time. DMP's existing footprint is in North America, but its technology is relevant around the world. There is a great growth opportunity in taking this business to our global customer base. Environmental matters are existential for our customers, and we are excited to help provide them with yet another set of critical solutions. We are very happy to welcome the DMP team into the ESI family."

16:12 EDT Tilray says Maryscott Greenwood intends to resign as member of board - Tilray said: "Maryscott Greenwood intends to resign as a member of our board of directors and all committees thereof, effective as of September 30, 2020. The company is grateful for Ms. Greenwood's contributions to Tilray. Effective August 6, 2020, Soren Schroder has been appointed as a Director on the Tilray Board. Soren has served in a variety of agribusiness leadership roles in the United States and Europe. After working for more than 15 years at Continental Grain and Cargill, he joined Bunge Ltd in 2000. Soren served as CEO of Bunge North America, leading Bunge's business operations in the United States, Canada, and Mexico. In June 2013, he was named CEO of Bunge Ltd, serving in this role until 2019. Soren is active in board and advisory roles for emerging companies in the agribusiness and food sectors. His experience lies in building global supply chains, managing risk, logisitics, industrial and value-added activities, and executing on strategy via acquisitions and partnerships on a global scale."

16:06 EDT Installed Building Products buys North Charleston, SC and Pooler, GA branches - Installed Building Products announced it has acquired the North Charleston, SC and Pooler, GA branches from Energy One America, LLC. The acquired branches will operate under the names, Charleston Insulation and Foam and Savannah Insulation and Foam, respectively. Both branches offer spray foam, fiberglass, and air barrier installation services to residential, multi-family and commercial customers.

16:04 EDT Peck to acquire Sunworks via share exchange - The Peck Company Holdings, Inc. (PECK) and Sunworks, Inc. (SUNW) announced that they have entered into a denitive agreement under which Peck will acquire Sunworks in an all-stock transaction, pursuant to which each share of Sunworks common stock will be exchanged for 0.185171 shares of Peck common stock. Assuming no adjustments, Sunworks' stockholders would receive an aggregate of approximately 3,079,207 shares of Peck common stock, representing approximately 36.54% of Peck common stock outstanding after the merger. The transaction is expected to close during the fourth quarter of 2020, subject to approval by shareholders of both companies and other customary closing conditions. The Board of Directors of Peck and Sunworks have each unanimously voted in favor of the definitive transaction agreement.

15:13 EDT Berkshire Hills Bancorp trading resumes

14:45 EDT Berkshire Hills Bancorp trading halted, news pending

14:32 EDT Actinium Pharmaceuticals announces 1-for-30 reverse split of its common stock - Actinium Pharmaceuticals announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding common stock that will become effective after trading closes on August 10. Trading of the Company common stock will begin on a split-adjusted basis when markets open on August 11.

13:08 EDT Nikola chairman says first of three 'promised achievements' completed - After this morning's announcement that Republic Services (RSG) is partnering with Nikola Corp. (NKLA) to develop and purchase 2,500 electric waste and recycling collection trucks, Nikola founder and Executive Chairman Trevor Milton tweeted: "I will be on @CNBCFastMoney today to discuss the 2,500 - 5,000 (1-2 billion dollar) binding truck order! I promised 3 achievements by years end. The first is now complete 4 months ahead of schedule - Announcing a world class binding contract for vehicles." Reference Link

12:00 EDT GSX Techedu falls -9.2% - GSX Techedu is down -9.2%, or -$9.85 to $97.14.

12:00 EDT Eastman Kodak falls -28.6% - Eastman Kodak is down -28.6%, or -$4.25 to $10.63.

12:00 EDT LightInTheBox rises 20.0% - LightInTheBox is up 20.0%, or 55c to $3.31.

11:51 EDT EA Access to soon be available on Steam - Electronic Arts' subscription service for PC games, known as EA Access, will soon become available on Steam, one of the biggest PC game marketplaces. "Don't just get the game. Get more from your game with EA Access -- it's the ultimate game membership for anyone who loves EA games," EA said on the service's Steam page. "Follow EA and you'll be notified as soon as EA Access is available." Reference Link

11:06 EDT Generac announces new products, capabilities to PWRcell product line - Generac Power Systems announced that it is introducing new products and capabilities to the PWRcell product line that "make Generac's PWRcell the first end-to-end solar and storage system to be capable of providing intelligently managed backup power to the entire home." The products include the new PWRcell Automatic Transfer Switch, known as the PWRcell ATS, with integrated load management; new higher-capacity batteries rated up to 18 kWh; and an outdoor-rated enclosure that "allows for a simple, flexible and 100% outdoor installation," the company stated in a press release.

10:37 EDT Canopy Growth expects gross margins to be pressured, sees Q2 GM below 20% - Comments taken from Q1 earnings conference call.

10:34 EDT Kelly Services appoints Amy Bouque as CHRO, Jocelyn Lincoln as CTOAlly Financial - Kelly (KELYA) named Amy Bouque as its new chief HR officer focused on full-time employees, and Jocelyn Lincoln as chief talent officer focused on the temporary worker experience. Amy Bouque joins Kelly from Ally Financial (ALLY), where she has served as Executive Director of Talent Management since 2014. Jocelyn Lincoln has spent 21 years leading numerous marketing and candidate-focused teams at Kelly, most recently as Vice President of Global Business Planning and Experience. een understanding of temporary workers' diverse motivations and the ability to keep human connections at the heart of a fast-paced digital strategy. She has balanced both the art and science of talent throughout her career.

10:18 EDT Interactive Brokers ordered by CFTC to pay more than $12M for violations - The Commodity Futures Trading Commission filed and simultaneously settled charges against Interactive Brokers LLC, a registered futures commission merchant, for failing to diligently supervise its officers', employees', and agents' handling of several commodity trading accounts and failing to adequately implement procedures to detect and report suspicious transactions as required under federal anti-money laundering laws and regulations. The order requires Interactive Brokers to pay a civil monetary penalty of $11.5M and disgorge $706,214 earned in part from its role as the FCM carrying the accounts of Haena Park and her companies, which were the subject of a 2018 CFTC enforcement action. According to the order, from June 2014 through November 2018, Interactive Brokers failed to ensure that its employees followed established policies and procedures with respect to supervision of customer accounts. Interactive Brokers also lacked a reasonably designed process for conducting investigations of account activity and making SAR determinations.

10:00 EDT Accenture acquires Organize Cloud Labs; financial terms not disclosed - Accenture has acquired Organize Cloud Labs, a Brazil-based company operating as ServiceNow's first Elite partner in Latin America. The acquisition strengthens Accenture's already vast information technology capabilities and deep industry experience in cloud strategy, migration, implementation and management, the company said in a statement. "The combination of Accenture's global ServiceNow experience and the local skills acquired through Organize Cloud Labs will strengthen our ability to help local clients ensure business resilience," said Paulo Ossamu, who leads Accenture Technology in Latin America. "The acquisition will enhance our position as a leader in ServiceNow capabilities steeped in strategy, business and industry knowledge and, most importantly, strong cloud talent."

10:00 EDT MGM Resorts rises 17.4% - MGM Resorts is up 17.4%, or $3.31 to $22.34.

09:56 EDT Interactive Brokers to pay $38M to settle with regulators over SARs - The Securities and Exchange Commission announced that Interactive Brokers will pay an $11.5M penalty to settle charges it repeatedly failed to file Suspicious Activity Reports, or SARs, for U.S. microcap securities trades it executed on behalf of its customers. In parallel actions, the Financial Industry Regulatory Authority, or FINRA, and the Commodity Futures Trading Commission, or CFTC, announced settlements with Interactive Brokers related to anti-money laundering failures in which the registered broker-dealer agreed to pay penalties of $15M and $11.5M, respectively, for a total of $38M in penalties paid to the three agencies, the SEC reported.

09:47 EDT Radian Group falls -7.1% - Radian Group is down -7.1%, or -$1.11 to $14.53.

09:47 EDT Flagstar Bancorp falls -8.6% - Flagstar Bancorp is down -8.6%, or -$2.81 to $30.02.

09:47 EDT Canopy Growth rises 11.6% - Canopy Growth is up 11.6%, or $1.93 to $18.56.

09:47 EDT MGM Resorts rises 20.4% - MGM Resorts is up 20.4%, or $3.89 to $22.92.

09:38 EDT Conformis says study reports 90% patient sastifaction post knee replacements - Conformis announced that 90% of the patients studied in peer-reviewed clinical research published online in The Journal of Bone and Joint Surgery Reviews were satisfied, or very satisfied, 18-28 months post-surgery. In addition, 88% of patients reported that their knees felt natural either some or all of the time. The clinical study, conducted by renowned U.S. orthopedic surgeons Vivekanand Neginhal and William Kurtz, and researcher Lennart Schroeder, was designed to test the hypothesis that the Conformis PS implant would drive high overall patient-reported outcomes because of its patient-specific design. In addition to patient satisfaction rates, patient-reported outcomes were assessed utilizing the Knee injury and Osteoarthritis Outcome Score Joint Replacement. KOOS JR interval scores range from 0 to 100, and the average score for the patients studied was 90. The researchers also found that the average preoperative baseline pain rating of 6.5 for the patients studied decreased by 5.2 on the numeric pain rating scale to an average of 1.3, which reflects a dramatic reduction in pain. The final measure assessed was implant survivorship, which was found to be 100% at an average of 23 months post-op for the 100 knees included in the study.

09:32 EDT Diffusion expects cash, cash equivalents to fund operations into 4Q21 - Diffusion had cash and cash equivalents of $25.6 million as of June 30, 2020, compared with $14.2 million as of December 31, 2019. During the second quarter the Company completed an offering of 11.4 million shares of common stock for net proceeds of $10.3 million. In addition, the Company received proceeds of $7.6 million from the exercise of 13.0 million warrants and the exchange and exercise of a further 5.0 million warrants. Diffusion believes its cash and cash equivalents as of June 30, 2020 are sufficient to fund operating expenses and capital expenditures, including clinical trials, into the fourth quarter of 2021.

09:30 EDT Galectin Therapeutics expects cash to fund operations through at least Sept. 30 - As of June 30, 2020, the Company had $40.8 million of cash and cash equivalents. The Company also has a $10 million unsecured line of credit, under which no borrowings have been made to date. The Company believes it has sufficient cash, including availability under the line of credit, to fund currently planned operations and research and development activities through at least September 30, 2021.

09:18 EDT Marriott says recovery in China 'well apace' - Says "Chinese by and large back to traveling again." Says small firms driving modest growth in business travel.

09:17 EDT Seelos receives FDA clearance for Phase IIb/III trial studying SLS-005 - Seelos Therapeutics announced that, on August 7, it was notified by the FDA that Seelos may proceed with initiating a Phase IIb/III trial studying SLS-005, or trehalose, for the treatment of Amyotrophic lateral sclerosis, or ALS. Mutations in the C9orf72, SOD1, FUS, and TARDBP genes can cause familial ALS and contribute to the development of sporadic ALS. These mutations contribute to the death of motor neurons and ALS affected motor neurons develop a buildup of protein aggregates such as TDP-43 and SOD1. In in-vivo studies of ALS, trehalose has been shown to increase clearance of TDP-43, decrease SOD1 and SQSM1/p62 aggregates and monomers, delay the progression of the disease, preserve ventral horn motor neurons and increase muscle fiber size.onal signs of disease progression.

09:15 EDT Republic Services to purchase 2,500 electric collection trucks from Nikola - Republic Services (RSG) announced a partnership with Nikola Corp. (NKLA) to develop and purchase 2,500 electric waste and recycling collection trucks, which the company said represents "the industry's first large-scale commitment to fleet electrification." The zero-emissions vehicles, which will have a range of 150 miles and recharge overnight, are expected to be integrated into Republic Services' fleet beginning in 2023. The deal is expandable to 5,000 vehicles over the life of the agreement. In pre-market trading following the deal announcement, Nikola shares are up $5.07, or 13.8%, to $41.79.

09:15 EDT MGM Resorts jumps 16% to $22.09 after IAC takes 12% stake in company

09:14 EDT Navidea, Jubilant Radiopharma sign binding MOU for commercialization partnership - Jubilant Radiopharma, a business unit of Jubilant Pharma, and Navidea Biopharmaceuticals, announced that both companies have signed a binding memorandum of understanding, or MOU. The companies said in a release, "The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement, or ELDA, for Navidea's diagnostic imaging agent Tilmanocept (technetium Tc 99m tilmanocept injection) in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant Radiopharma also made a $1 million equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed. Tilmanocept, which is entering Phase 3 clinical trials for approval by the FDA, will enable Nuclear Medicine departments to visually and quantifiably localize and monitor activated macrophages in patients suspected of having rheumatoid arthritis, or RA. RA is a painful long-term autoimmune disorder that primarily affects joints in the human body resulting in long term damage if left untreated. In the United States over 1.3 million Americans suffer from this disease."

09:12 EDT Moxian signs LOI with Btab Group - Moxian announced the signing of a Letter of Intent with Btab Group Inc., a Delaware corporation , pursuant to which the two corporations will further negotiate, and if the terms are agreed, enter into a Merger Agreement for a business combination. The terms of the Merger have not been finalized but it is contemplated that the Company will issue both common and preferred shares in exchange for the common shares of Btab. The Merger will also be subject to certain conditions, including a satisfactory completion of due diligence and an audit of past financial statements. Btab Group Inc was established as a holding company in 2018 with a central location in Sydney, Australia and has offices in Australia, China, the United Kingdom and the United States of America. Btab is an e-commerce services provider and a product supplier to small businesses with total unaudited assets in excess of $100 million as of June 30, 2020. It currently operates through subsidiaries in Australia but has plans to expand into South-east Asia and other emerging markets. Btab aims to provide affordable online technology to small businesses to allow them to compete with the technology that big companies are using. Services offered include building a marketing platform across the Btab network, providing managed e-commerce services, securing useful domain names and creating social marketplaces. The motto of the company is to serve the underserved market. It is believed that every small business deserves an equal opportunity to empower its supply chain and succeed in the modern retail market.

09:10 EDT BioElectronics chairman outlines new direction for company - BioElectronics released a Chairman's Letter to Shareholders written by Dr. Richard Staelin, the Company's Chairman of the Board. "The purpose of this letter is to update you on the activities of BioElectronics Corporation over the last 10 months, their results, and the impact of these activities on the future of the Company. Although many are probably most eager to learn about these results, I encourage you to also read my discussion on the underlying logic which led us to where we are today, since it is this logic that forms the foundation that will drive your Company forward over the foreseeable future... We now have signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. These three companies will be selling our devices into the United States over-the-counterconsumer health retail market. They will differentiate their offerings by utilizing different retail channels, branding strategies, and attachment systems. Their retail launch dates vary but are currently scheduled between Q4 of 2020 and Q2 of 2021, reflecting industry practice for retailers to plan launch times six to nine months into the future. We also have a signed agreement with a commercial firm that is in the process of recruiting and training up to 400 independent sales representatives who will actively sell our RecoveryRx postoperative pain product line into doctors' offices, wound clinics, nursing facilities, and hospitals. As with the three OTC retail-oriented companies mentioned above, we will act as the original equipment manufacturer for this sales force, providing them with devices upon receiving purchase orders. The principles of this sales force anticipate that sales will begin in Q4 of 2020 and ramp up over the next calendar year. As an OEM we must respect all of these buyers' requests not to reveal any specific information about their identity or marketing and sales plans. However, at the appropriate time, probably after retail product launches, BioElectronics will provide more information about each venture in news releases. In terms of international sales, we recently signed a licensing agreement with a major international company and are in the final stages of signing an agreement with another large international company. Both of these companies need to register our products with their respective local medical regulatory authorities before they can distribute and sell our products. In addition, the sales force of our long-standing distributor, Mundipharma, has reentered the field after a slow down of sales activity due to the pandemic. Based in part on this new activity, they are forecasting a reorder in Q4 of 2020. Our engineering and clinical team has continued to improve our understanding of the mechanism of action for the technology behind our devices and to develop new versions of our products. In addition, in conjunction with some of our new sales representatives, we are in the process of establishing new clinical alliances to further strengthen the clinical evidence on our devices. In early November of 2019 senior leadership started working on developing a long-term strategy that would allow the Company to better compete and thrive in the pain care health market. This team was composed of the current Board, Kelly Whelan, Keith Nalepka, and myself, and augmented by Dr. Sree Koneru who heads up our product development team. Early on, this group concluded that the Company's core capabilities were its deep knowledge and experience in Pulsed Short Wave Therapy technology which is the use of non-thermal, high-frequency electromagnetic fields for therapeutic purposes. This knowledge had already enabled the Company to acquire three 510(k) clearances from the U.S. Food & Drug Administration. This expertise also allowed the Company, working with its trusted manufacturer, to develop processes that enabled mass production of high quality, effective, low cost PSWT devices. The group felt that these two core assets not only allowed the Company to successfully compete in the United States medical and retail markets, but also efficiently a) develop new product offerings that would better serve different segments of the pain management market; and b) launch new initiatives into other neurological ailments linked to chronic pain, such as overactive bladder and migraine headaches...The group quickly coalesced around the strategy of not trying to directly sell its existing products into either the medical or retail markets in the United States but instead becoming an efficient, low-cost original equipment manufacturer that would form strong relationships with other companies that not only had the financial resources, but also the marketing expertise and knowledge to effectively introduce our devices into these markets. With this noted, we also decided to strengthen the Company's international footprint, by continuing to contract with noted international companies and provide them with products and clinical evidence that would help them be successful...Armed with the OEM strategy, we aggressively pursued activities intended to support this two-pronged selling approach. Members of the sales team began communicating with several potential domestic and international companies. Concurrently, a major effort was initiated by our regulatory and engineering staff to accelerate the renewal of our CE mark, thereby allowing us to export product to the EU and other international markets."

09:07 EDT Wrap Technologies receives multiple international BolaWrap orders - Wrap Technologies said in a release, "Wrap Technologies announced that it received new international orders for BolaWrap products and accessories. The orders are from the following: Two new law enforcement agencies in Canada; One new customer in South America; One new customer in the Middle East; One follow on order from the Middle East. Completion of these orders will increase Wrap's presence from 27 to 29 countries."

09:01 EDT IAC acquires 12% interest in MGM Resorts for about $1B - IAC (IAC) announced its accumulation of a 12% interest in MGM Resorts International (MGM) for an aggregate of approximately $1B. "With the separation of Match Group from IAC, and 'new' IAC emerging with $3.9 billion of cash, no debt, and its opportunistic zeal intact, we are energized and excited to make this investment in MGM. What initially attracted us to MGM, besides its leadership in leisure, hospitality and gaming, was an area that currently comprises a tiny portion of its revenue - online gaming," said Barry Diller, Chairman and Senior Executive of IAC. "IAC's foundational concept of seeking opportunities to build interactive businesses is our base rationale - there is a digital first opportunity within MGM Resorts' already impressive offline businesses, and with our experience we hope we can strongly contribute to the growth of online gaming." "MGM Resorts presents a unique opportunity for IAC to own a meaningful piece of a preeminent brand in a large category with immense potential to move online," said Joey Levin, CEO of IAC. "We will be a minority investor and a long-term strategic partner, and would welcome the opportunity to contribute to MGM's success in any way that MGM's Board would look favorably on our involvement."

08:58 EDT Datasea receives second subsidy from Harbin Municipal Government - Datasea announced that it has been selected to receive a subsidy in the amount of RMB 300,000 from the Harbin Municipal Government to enhance and customize its Safe Campus Management System. Harbin Municipal Government recently launched its "Eagle Plan" to provide additional funds to companies with innovative technologies for research and development purposes. Following the review process, the Company was selected to receive the government subsidy.

08:57 EDT Radius Health appoints Sean Murphy to board of directors - Radius Health announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean worked at Abbott Laboratories for 30-years where he led the corporate business development and mergers and acquisition activity.

08:55 EDT Marriott sees monthly cash burn of $85M with RevPAR down 70%

08:54 EDT CCL Industries to acquire Graphic West for approx. C$36M - CCL Industries announced it has signed a binding agreement to acquire Graphic West International, a specialized digital printer of short-run folding cartons for the pharmaceutical and medical device industries with operations in Europe and North America. GWI is headquartered in Horsholm, Denmark, with manufacturing operations in Nowogard, Poland, and Tyler, Texas, in the United States, The enterprise value of the transaction, net of cash and debt, is approximately C$36 million. Sales for the twelve months ending June 30, 2020, are approximately C$42 million with an estimated adjusted EBITDA of C$6 million. GWI will be integrated into CCL's Healthcare & Specialty business and will immediately adopt their trading identity.

08:53 EDT Xtant announces debt restructuring - Xtant Medical Holdings announced that it has entered into a Restructuring and Exchange Agreement with the lenders under its credit facility pursuant to which the parties agreed to take certain actions to restructure Xtant's outstanding indebtedness, including the exchange of certain indebtedness outstanding under the facility, together with accrued and unpaid interest thereon, into shares of Xtant common stock. The primary purpose of the restructuring is to improve Xtant's capital structure by reducing its outstanding debt, which the Company expects will facilitate future access to capital markets for investment in its growth initiatives, and provide a path to possibly regain compliance with the NYSE American continued listing standards. The restructuring transactions contemplated under the Restructuring and Exchange Agreement include, among others: an amendment to Xtant's charter to increase the number of authorized shares of common stock from 75 million to 300 million; the exchange by Xtant of shares of common stock for approximately $40.8 million of the aggregate outstanding principal amount of the loans outstanding under the credit agreement, as well as, without duplication, approximately $21.1 million of the outstanding amount of PIK Interest, plus all other accrued and unpaid interest on the exchanging loans outstanding as of the closing date, at an exchange price of $1.07 per share, representing the average closing price of the common stock over the 10 trading days immediately prior to the parties entering into the Restructuring and Exchange Agreement, and resulting in the issuance of approximately 57.8 million shares of Xtant common stock to the lenders; the execution of an amendment to the credit agreement by the parties thereto to change certain provisions therein, including extinguishing loans in an aggregate principal amount equal to the exchanging loans outstanding thereunder together with all accrued and unpaid interest thereon, adding loans in an aggregate principal amount equal to the prepayment fee payable thereunder in respect of the exchanging loans, reducing the amount of credit availability thereunder, reducing the interest rate and eliminating certain financial covenants; and the launch by Xtant of a rights offering to allow stockholders of the Company to purchase up to an aggregate of $15 million of Xtant common stock at the same price per share as the $1.07 per share exchange price used to exchange the exchanging loans into common stock. Immediately after the signing of the Restructuring and Exchange Agreement, Xtant solicited and obtained the written consent of OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, the holders of an aggregate of approximately 9.25 million shares of common stock, representing a majority of the outstanding shares of Xtant common stock as of the record date, August 7, 2020, for the approval of the charter amendment and the share issuance. The written consent of these two stockholders was sufficient to approve the charter amendment and the share issuance. Therefore, no proxies or additional consents will be solicited by Xtant in connection with the transaction. Pursuant to applicable federal securities and corporate laws, Xtant intends to file an information statement with the Securities and Exchange Commission and send it to all holders of its common stock as of August 7, 2020 for the purpose of informing such stockholders of the written actions taken by the two consenting stockholders. In accordance with applicable federal securities laws, the stockholder consent of the two consenting stockholders will become effective no sooner than 20 calendar days following the mailing of the information statement. After the expiration of this 20-day period, Xtant intends to file the charter amendment with the Secretary of State of the State of Delaware and, immediately thereafter, issue the 57.8 million shares of common stock to the lenders in exchange for the exchanging loans. After completion of that transaction, Xtant intends to commence a rights offering to provide all stockholders as of a record date to be determined at a future date the opportunity to purchase Xtant common stock at the same price per share as the $1.07 exchange price used in the debt restructuring.

08:51 EDT Chipotle teams up with Tony Hawk - Chipotle Mexican Grill announced it is teaming up with skating legend and brand superfan Tony Hawk to offer his go-to Chipotle order exclusively on the Chipotle app and Chipotle.com. Starting today, the first 2,000 fans who order the Tony Hawk Burrito, made with brown rice, black beans, chicken, tomatillo-red chili salsa and guac, will get access to the Tony Hawk's Pro Skater 1 and 2 Warehouse Demo for PlayStation 4, Xbox One, or PC.

08:45 EDT Aeglea BioTherapeutics expects capital to fund operations through 2022 - As of June 30, 2020, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $159.2 million. Based on Aeglea's current operating plans, management believes it has sufficient capital resources to fund anticipated operations through 2022.

08:43 EDT Turning Point Therapeutics expects cash to fund operations into 2023 - Cash, cash equivalents and marketable securities at June 30 totaled $710.4 million, an increase of $329.6 million from Mar. 31 driven by proceeds from the company's May stock offering. Turning Point Therapeutics projects its cash position funds current operations into 2023.

08:41 EDT Select Interior Concepts announces employment inducement award - Select Interior Concepts announced that in connection with the appointment of Deme Christian as Chief Human Resources Officer of the Company, effective immediately, the Company granted to Ms. Christian 62,500 time-based restricted stock units and 62,500 performance-based restricted stock units, each representing the right to earn one share of the Company's common stock. The time-based restricted stock units vest in equal annual installments over four years, subject to Ms. Christian's continued employment with the Company. The performance-based restricted stock units vest based on the closing price of the Company's common stock exceeding specific price hurdles for 20 consecutive trading days, and subject to Ms. Christian's continued employment with the Company. The restricted stock units were negotiated and approved as an inducement to Ms. Christian's entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

08:40 EDT Inpixon receives FCC certification for its UWB module - Inpixon announced it has received certification for its Ultra-WideBand, or UWB, module from the U.S. FCC. The FCC-certified UWB module is designed and developed by Inpixon for use in Inpixon and third-party sensors, built to meet the IEEE 802.15.4 UWB standard and has an ability to provide positional accuracy of under 30 centimeters.

08:39 EDT Bionano Genomics announces multiple data readouts at CGC - Bionano Genomics announced that the 2020 Cancer Genomics Consortium Annual Meeting held on August 4 and 5 featured several studies using Bionano genome imaging. Results of these studies underscore that Saphyr has the potential to modernize cytogenetics by consolidating analysis performed with each of the three standard cytogenetic methods into a single assay with performance that matches or exceeds that of these three methods combined. The Cancer Genomics Consortium is an organization comprised of leading cytogeneticists, molecular geneticists and molecular pathologists. Its annual meeting attracts the key opinion leaders and cytogenetics directors from North America's leading cancer centers and hospitals. In the last several years, the meeting has seen an increasing presence of studies and presentations featuring data generated using Bionano's Saphyr genome imaging system. At this year's virtual event, four speakers shared their results generated with Saphyr. Dr. Gordana Raca from the Children's Hospital of Los Angeles presented the case of a 2-year old boy with B-cell acute lymphoblastic leukemia who had been tested by the traditional methods of karyotyping, an extensive FISH panel and chromosomal microarray, as well as with an advanced custom sequencing panel for pediatric cancer, with no genetic driver of the disease found. CMA analysis called a duplication in the PAX5 gene, a known oncogene, but upon analysis with Saphyr, the two extra copies of the gene were shown to be four extra copies in tandem. In a second child with similar disease, Saphyr called five extra copies of the same oncogene, while CMA called only 2. The unambiguous resolution of these variants by Saphyr demonstrated the advantage of genome imaging of single molecules over hybridization-based methods like CMA. The extra copies of parts of the PAX5 gene are believed to be the primary driver of the disease in the patients, and to be correlated with a poor prognosis, including relapse and more severe progression of the disease. Dr. Nikhil Sahajpal from Augusta University presented results on 20 cancer patients, including leukemia patients with acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndromes who were previously characterized by karyotyping and FISH analysis, and patients with solid tumors, previously characterized by OncoScan microarray. In all samples, Saphyr detected all previously found variants. Additionally, Saphyr identified variants that were not called by karyotyping and FISH, contributing to resolution of complex rearrangements with previously unclear structure, and the identification of precise breakpoints of pathogenic variants and many previously unknown translocation partners. In the solid tumor samples, Saphyr identified all previously identified events and also identified multiple translocations that are impossible to detect by microarray. These results form the basis for creating a Laboratory Developed Test for cancer by Dr. Ravindra Kolhe's team at Augusta University. The project aims to validate Saphyr as a first-tier diagnostic tool for solid tumors and hematological malignancies and to lay the groundwork for reimbursement codes for labs based in the United States. In addition to those new results, Dr. Alex Hoischen from Radboud Univeristy presented the previous reported validation studies by his team and an international consortium on 48 leukemia samples and 85 patients with constitutional disease, both showing 100% concordance between Saphyr and standard cytogenetics. Dr Hoischen also presented certain novel research findings, including new genetic variants that could form the basis of more refined testing algorithms in the future. Talks at CGC covering other technologies including long-read sequencing and nanopore sequencing provided additional support for Bionano genome imaging with Saphyr as a leading technology for modernizing cytogenetics. For example, Evan Eichler from the University of Washington discussed in his keynote talk on various long-read genome analysis technologies that the largest structural variants can be detected by Bionano genome imaging but not by long-read sequencing. Finally, in a presentation on nanopore sequencing, Dr. William Gleen from Medical University of South Carolina described the need to use 10 different bioinformatic algorithms to obtain a set of structural variation calls, yet this data included a high rate of wrong calls.

08:38 EDT NCR Corp. selected by Police Credit Union for digital banking experience - NCR Corporation said in a release, "NCR Corporation announced that The Police Credit Union, which serves California law enforcement members and their families, selected NCR to transform its digital banking experience to support the credit union's recent expansion of membership availability to the entire state. The NCR Digital Banking platform allows credit unions and banks to expand services for consumers and businesses and offer a better overall experience. By moving to the NCR DI Digital Banking platform for community financial institutions, the credit union will offer its members a more personalized experience including business banking, digital credit score and live chat. Partnering with NCR will allow The Police Credit Union to deliver consumer and business banking on a single platform for the first time, simplifying operations, reducing costs and enabling a more connected experience for members."

08:37 EDT Cumulus Media to monetize Tower Portfolio for $213M - Expect funds from deal completion to permit substantial debt paydown and provide additional liquidity; Anticipate first closing for 85% or more of proceeds in Q4

08:34 EDT Vaxart files IND for COVID-19 vaccine - Vaxart announced that its COVID-19 Investigational New Drug application has been filed with the US Food and Drug Administration.

08:31 EDT Spark Therapeutics appoints Gallia Levy as CMO - Spark Therapeutics announced the appointment of Gallia Levy, M.D., Ph.D., as chief medical officer. Dr. Levy will be responsible for strategic and operational leadership across all functions in the product development lifecycle, including setting the global development strategy for current and future pipeline programs. Levy joins Spark Therapeutics from Genentech, also a member of the Roche Group, where she served as the Vice President and Global Head of the Rare Blood Disorders franchise in Product Development.

08:29 EDT Brown & Brown to acquire Hauser, terms not disclosed - J. Scott Penny, Chief Acquisitions Officer of Brown & Brown, and Mark Hauser, Chairman of HAUSER announced that Brown & Brown, has entered into an agreement to acquire the assets of HAUSER. The transaction is expected to close in September 2020, subject to certain closing conditions. HAUSER focuses on unique insurance solutions for private equity groups and their portfolio companies inclusive of M&A advisory and due diligence services, placement of insurance solutions for all aspects of business risk, employee benefits advisory services and 401(k) plan compliance. The agency was founded 50 years ago by the Hauser family and, under the leadership of Mark Hauser and James Stines, has developed deep specialization in M&A and risk advisory services for the private equity industry. HAUSER will continue to operate from its headquarters in Cincinnati, Ohio, led by James Stines.

08:27 EDT Myriad announces publication on limitations of ethnicity-based guidelines - Myriad Genetics announced a new study published in the peer-reviewed journal Genetics in Medicine demonstrates the limitations of ethnicity-based medical guidelines in identifying couples at risk for a pregnancy affected by serious genetic conditions. The analysis of 93,419 individuals found substantial discordance between self-reported ethnicity and actual genetic ancestry. In the new study, researchers at Myriad assessed the ability of a 96-disease screen to identify carriers in an ethnically diverse population, comparing the results to those obtainable via ethnicity-based screening. They also compared the genetic ancestry of the population to self-reported ethnicity. Results showed that only 23 percent of carriers would have been identified through ethnicity-based screening protocols supported by societal guidelines. Further, for seven of the 16 diseases included in the guidelines, most carriers were not from the populations that the American College of Obstetricians and Gynecologists and the American College of Medical Genetics and Genomics have indicated were at higher risk of the respective genetic disorders. In the past decade, the evolution of carrier screening methodology has enabled scalable screening of many serious single-gene diseases simultaneously, termed expanded carrier screening. Although panethnic ECS, as offered to all patients without regard to ethnicity, has established analytical validity, clinical validity, clinical utility, and cost-effectiveness, both ACOG and ACMG currently stop short of recommending that ECS be preferentially offered. Instead, screening based on self-reported ethnicity continues to be endorsed as a standard. Carrier screening identifies pregnancies at increased risk of serious genetic conditions that may reduce lifespan, result in intellectual disability or that would benefit from prenatal or perinatal intervention. Carrier screening is typically performed by first identifying females who are carriers for autosomal recessive or X-linked conditions, and subsequently testing their reproductive partners for those same conditions. Under current guidelines from ACOG and ACMG, only cystic fibrosis and spinal muscular atrophy carrier screening should be offered to all who are pregnant or considering pregnancy, and screening for a small number of additional conditions should be offered only in those who self-report and are based upon ethnicity.

08:25 EDT Genius Brands files proxy statement in connection with special meeting - Genius Brands International filed a definitive proxy statement in connection with a special meeting of stockholders that will be held via live webcast at 10:00 a.m. Pacific Daylight Time, on Thursday, August 27, 2020. Genius Brands Chairman & CEO, Andy Heyward, sent the following letter to stockholders in connection with this filing: Today we filed a definitive proxy for a special meeting of stockholders to be held on Thursday, August 27, 2020. The purpose of this meeting is to amend our Articles of Incorporation to increase the authorized number of shares of Genius Brands International, Inc. common stock from 233 million to 400 million shares, and to adopt our 2020 Incentive Plan. Let me explain why we are doing this - and why your vote is important. I want to make sure that all our shareholders understand exactly why we have proposed this amendment and Incentive Plan, and why we are confident it is in the shareholders' interests. The purpose of these new shares will be to take advantage of unusual current opportunities to acquire assets in the consolidating entertainment space, which will be accretive to the company. It will additionally, enable us to attract, motivate, and retain qualified individuals upon whom our business and accretive growth strategy to create value, depends. Normally, people associate the issuance of shares with dilution, however when the dilution is accretive, the benefit to the company is exceeded by the acquisition of the asset, and is greater than the dilutive effect. That is the primary purpose of having these new shares available. I speak not only as your Chairman and CEO, but as one of the largest shareholders in the company, whose interests are fully aligned with those of our shareholders of common stock to create value. We have only one class of voting stock, it is common stock and mine is the exact same as all other shareholders. Today, there is great consolidation going on in the entertainment industry. There are valuable program and distribution assets available and a smart company able to be nimble, can acquire them on extremely attractive terms, and may witness values that might not be available for a long time. The Genius common stock is a valuable currency that I believe will enable us to do that. One only needs to look at The Walt Disney Company's 'playbook', to see the value changing transformation of important assets....all acquired through issuance of new stock... Imagine what the Walt Disney Company would have been today without having moved to acquire Pixar, LucasFilm, or Marvel. We believe there are opportunities today for Genius Brands as well, which can be equally as important for our own growing company. The preponderance of the proposed authorized shares are targeted to fuel growth. Separately, the 2020 Incentive Plan will enable us to retain and motivate the qualified individuals upon whom our business and accretive growth strategy depend, as well as attract new employees with accomplished pedigrees, to further support our growth strategy. I have often spoken about the caliber of our management team, and its pedigree from the top of the most successful companies in Hollywood. I also want to draw attention to the pedigree of your Board of Directors. We have the former Managing Director of Entertainment at J.P. Morgan, one of the largest banks in the world, with a leading global media mergers and acquisitions practice. We have the former Governor of California, the former President of ABC Entertainment, and the former Head of Entertainment for Bear Stearns. Margaret Loesch, the former President of Marvel Entertainment and Founder of FOX Kids, which was eventually sold to the Walt Disney Company for $5.5 Billion dollars, David Neuman, the former President of Walt Disney Television, and Caroline Tyre, who launched Cartoon Network Canada, is the leadership team that recently has brought Kartoon Channel! into the marketplace. Just a week ago we announced the launch of Kartoon Channel! on iOS with the debut of an all-new dedicated Kartoon Channel! app, available free on Apple iOS - to a stunning reception. In just the first 24 hours of availability, our app reached the Top 10 for kids and received thousands of 5-star ratings. This is the kind of talent that is joining Genius Brands to lead our growth strategy going forward. Having them motivated with common stock like us all, is the best tool for talent acquisition and retention. We are focused and determined to grow Genius Brands into the leader in children's and family entertainment. As Genius Brand's largest shareholder, I can say wholeheartedly that my interests are aligned with our shareholders to create value, and all of us in management and your board are committed to doing what's in our shareholders' best interests. We urge you to vote in favor of all proposals at the special meeting. If you have any questions, please contact the Company's proxy solicitor, Morrow Sodali."

08:22 EDT Antares Pharma appoints Tram Bui as VP, corporate communications - Antares Pharma announced the appointment of Tram Bui as Vice President of Corporate Communications and Investor Relations. Ms. Bui will succeed Jack Howarth, Vice President of Corporate Affairs, upon his retirement on August 31, 2020. Tram will report to Fred Powell, Antares Pharma's CFO. Bui joins Antares Pharma with over 15 years of equity research, communications and investor relations experience. Most recently, she served as Senior Vice President, Investor Relations at The Ruth Group, a boutique investor relations and communications firm specializing in life science and medical technology industries.

08:19 EDT Radius Health expects cash to fund operations for at least 12 months - As of June 30, 2020, Radius had $126.3 million in cash, cash equivalents, restricted cash, and marketable securities. Based upon our cash, cash equivalents and marketable securities balance as of June 30, 2020, we believe that, prior to the consideration of potential proceeds from partnering and/or collaboration activities, we have sufficient capital to fund our development plans, U.S. commercial and other operational activities for at least twelve months from the date of this press release.

08:15 EDT Arcadia Biosciences announces partnership with Three Farm Daughters - Arcadia Biosciences announced the execution of a term sheet to form a strategic business venture with Three Farm Daughters, a majority female-owned North Dakota-based consumer food company, to develop and market food products using Arcadia's patented non-GMO GoodWheat technology. Together, the companies will develop Three Farm Daughters-branded food products such as flours, pastas and crackers that leverage the enhanced nutritional profiles of GoodWheat ingredients.

08:13 EDT Leidos awarded $649M contract by ACC-APG - Leidos has been awarded a task order by Army Contracting Command - Aberdeen Proving Ground, or ACC-APG, under the Responsive Strategic Sourcing for Services indefinite delivery/indefinite quantity contract. It has a total value of $649M and includes a one-year base period of performance followed by four one-year option periods. Work will be performed in various locations both within the Contiguous United States, or CONUS, and Outside the Contiguous United States, or OCONUS. Through this contract Leidos will provide pilot services, airborne sensor operators, hub and spoke operations/excursion support, staffing for the Intelligence Coordination Center, system training, logistics, aircraft and primary mission equipment maintenance and integration, configuration management and engineering support services in support of the program's DHC- 8 and King Air 300 aircraft.

08:12 EDT Vitamin Shoppe names Muriel Gonzalez Chief Merchandising and Marketing Officer - The Vitamin Shoppe announced it has appointed Muriel Gonzalez as Executive Vice President, Chief Merchandising and Marketing Officer, effective August 10. Gonzalez brings deep expertise from a distinguished, four-decades long career in senior roles at Macy's, Bergdorf Goodman, Estee Lauder, Saks Fifth Avenue, and Ann Taylor.

08:11 EDT Rubius Therapeutics sees cash runway into 2022 - As of June 30, 2020, cash, cash equivalents and investments were $236.5 million as compared to $283.3 million as of December 31, 2019, providing Rubius with a cash runway into 2022. During 2020, the Company used $68.6 million of cash to fund operations and $3.9 million to fund capital expenditures, consisting mostly of payments for assets purchased in 2019. In addition, during the second quarter, the Company drew down the third and final tranche of $25.0 million pursuant to its $75.0 million loan agreement with Solar Capital.

08:09 EDT Avadel Pharmaceuticals announces additional data from REST-ON study - Announced additional data from the REST-ON study: All three doses of FT218 studied were highly significant compared to placebo on secondary endpoints evaluating daytime sleepiness, sleep architecture, and other narcolepsy symptoms: FT218 was also significant compared to placebo for all sensitivity analyses of the three co-primary endpoints at all three doses; Detailed data for the secondary endpoints and sensitivity analyses will be presented at a scientific conference or in a peer-reviewed scientific publication

08:09 EDT PPL to sell UK utility business - PPL announced that it is initiating a formal process to sell its U.K. utility business in order to position PPL as a purely U.S.-focused utility holding company and create additional shareowner value. The decision to proceed with the sale process follows a comprehensive strategic review by PPL's Board of Directors that assessed the company's business mix and future growth opportunities. "We believe there is an opportunity to unlock significant value for PPL shareowners through the sale of Western Power Distribution (WPD) and the strategic repositioning of PPL's portfolio to be fully U.S.-based," said Vincent Sorgi, PPL president and CEO. "WPD is a very strong business that continues to perform exceptionally well as the premier distribution network operator group in the U.K., but we believe it continues to be undervalued by the market as part of PPL."

08:07 EDT Royal Caribbean sees $0.6B of CapEx for remainder of 2020 - The expected capital expenditures for the remainder of 2020 and 2021 are $0.6B and $1.8B, respectively. These expenditures are mostly related to newbuild projects. COVID-19 has impacted shipyard operations and will result in delivery delays for newbuilds. Currently, the company expects that three of the five ships originally scheduled for delivery between July of 2020 and December of 2021 will be delivered within the remaining time frame. Two of these ships are Silver Moon and Silver Dawn, with capacity lower than 600 berths.

08:06 EDT ACI Worldwide appoints Alvaro Monserrat as chief revenue officer - ACI Worldwide announced the appointment of senior technology executive Alvaro Monserrat as chief revenue officer. Monserrat most recently served as president of the imaging division at Nuance Communications. Additionally, Monserrat currently serves as a board member for itopia and Seacoast Bank, and previously held board seats at several high-growth technology organizations.

08:02 EDT Royal Caribbean estimates monthly cash burn $250M-$290M - The company estimates its cash burn to be, on average, in the range of approximately $250M-$290M per month during a prolonged suspension of operations. This range includes all interest expenses, including the increases driven by the latest capital raises. It also includes ongoing ship operating expenses, administrative expenses, hedging costs, expected necessary capital expenditures (net of committed financings in the case of newbuilds) and excludes cash refunds of customer deposits, commissions, debt obligations and cash inflows from new and existing bookings. The Company is considering ways to further reduce its average monthly cash burn under a further prolonged out-of-service scenario and during re-start of operations.

08:00 EDT Hoth Therapeutics announces licensing of IP rights to COVID-19 testing device - Hoth Therapeutics announced licensing the intellectual property rights relating to the development of a medical device that has the potential to allow public health professionals to immediately diagnose COVID-19 infection via breath sample and track through a mobile device from the George Washington University, or GW.

07:57 EDT Aquestive Therapeutics receives Fast Track designation for AQST-108 - Aquestive Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company's drug candidate AQST-108, a "first of its kind" oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reaction, including anaphylaxis, using Aquestive's proprietary PharmFilm technologies. Aquestive received confirmation from the FDA in July 2020 that the agency completed its safety review of its IND and concluded that the Company could proceed with the first planned PK clinical trials of AQST-108. As such, the Company expects to commence its first PK clinical trial utilizing a four-treatment crossover design to compare the pharmacokinetics and pharmacodynamics of AQST-108 to that of epinephrine administered as subcutaneous and intramuscular injections before the end of the third quarter of 2020.

07:51 EDT Wave Life Sciences expects cash, cash equivalents to fund operations into 4Q21 - Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the fourth quarter of 2021.

07:49 EDT Intra-Cellular sees topline results from Study 403 in 2H21 - Lumateperone in Bipolar Depression: Study 402, our Phase 3 study evaluating lumateperone as adjunctive therapy in bipolar depression, has completed clinical conduct and we anticipate reporting topline results from this study by mid-September 2020. This global study enrolled patients with major depressive episodes associated with either Bipolar I or Bipolar II disorder, who were randomized to receive lumateperone 42 mg, 28 mg or placebo once daily for six weeks, while being maintained on lithium or valproate as mood stabilizers. The primary endpoint is change from baseline on the Montgomery-Asberg Depression Rating Scale total score at week 6. Study 403, a Phase 3 global study evaluating lumateperone 42 mg as monotherapy in the treatment of depression in patients with Bipolar I or Bipolar II disorder, is ongoing. We anticipate reporting top-line results from this study in the second half of 2021.

07:46 EDT Paratek Pharmaceuticals expects cash to fund operations through end of 2023 - The Company now anticipates the initial BARDA procurement of 2,500 anthrax treatment courses valued at approximately $38 million to occur by the end of 2020 contingent on the completion of the pre-EUA application review by FDA. 2020 R&D and SG&A expense is now expected to be approximately $135 million compared to the prior guidance of $140 million, driven by an increased focus on operational efficiencies and other favorability driven by the COVID-19 pandemic. Excluding the BARDA R&D and onshoring cost reimbursement, R&D and SG&A expense is expected to be modestly lower when compared to 2019. Based upon our current operating plan, which includes estimated NUZYRA U.S. product revenue and cost reimbursement under the BARDA contract, we anticipate that our existing cash, cash equivalents and marketable securities of $186.8 million, as of June 30, 2020, provide for a cash runway through the end of 2023 with a pathway to cash flow break even. This anticipated pathway assumes the Company will be able to fund all company operating expenses, anticipated capital expenditures, and debt service, including repayment in full of the Hercules Loan and Security Agreement.

07:40 EDT Baudax Bio says efforts to commercialze ANJESO impacted by COVID-19 - The Company's efforts to commercialize ANJESO have been, and may continue to be, impacted by the COVID-19 pandemic. Hospitals have reduced and diverted staffing, diverted resources to patients suffering from COVID-19 and limited hospital access for nonpatients, including our sales professionals, which the Company believes may impact their marketing and commercialization efforts. The Company believes that the reduction in elective surgeries during the COVID-19 pandemic has and may continue to result in decreased demand for ANJESO. The Company anticipates that many hospitals and health care providers will continue to suffer negative financial consequences due to an increase in unexpected costs, including for additional staff, personal protective equipment and ventilators, along with a reduction in revenue due to fewer elective procedures being performed, which may result in a decreased demand for ANJESO. While access restrictions have eased in some locations, spikes of COVID-19 cases in certain states or regions may further impact the Company's sales force as access to hospitals may be restricted and elective surgeries may be limited in those areas. Due to the rapidly evolving environment, continued uncertainties from the impact of the COVID-19 global pandemic, and recent regional outbreaks that are impacting the recovery, the Company cannot estimate the full extent to which the Company's commercialization of ANJESO and financial results may be adversely impacted.

07:38 EDT Navidea, Jubilant sign MOU worth $19M for Rheumatoid Arthritis Diagnostic ELDA - Navidea announced that it has signed a binding memorandum of understanding, or MOU, with Jubilant Draximage. The MOU outlines the terms and framework for an exclusive license and distribution agreement, or ELDA, for Navidea's Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico and Latin America. In connection with the MOU, Jubilant made a $1M equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed. The investment was priced "at the market", which was the closing price of Navidea's common stock on the NYSE American immediately preceding the investment. The MOU outlines certain terms that are expected to be included in the ELDA, including: Jubilant to provide Navidea with an additional $19M in the form of stock purchases and license fees, subject to the achievement of certain milestones, to be used to fund Navidea's upcoming NAV3-32 and NAV3-33 trials. Jubilant will pay license fees and sales-based royalties to Navidea based on revenue generated from the sale of Navidea's Rheumatoid Arthritis Diagnostic in the licensed territory. Jubilant will serve as the exclusive commercial and distribution partner for Navidea's Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico and Latin America. Jubilant will be responsible for all commercialization efforts within the licensed territory. The execution of the ELDA is subject to certain conditions, including Jubilant's completion of due diligence. Navidea also announced that on August 9, 2020, it signed a binding commitment letter with Mastiff Group LLC, for a private placement financing of up to $25 million in aggregate gross proceeds of shares of Navidea's common stock. Shares will be priced either "at the market" or at a premium to Navidea's closing price on the date of execution (the "Private Placement Financing"). Navidea expects to sign definitive documents for a common stock only transaction, with an investor syndicate comprised of Mastiff Group LLC, John Kim Scott, Jr. and other fundamental biotech focused investors no later than August 18, 2020, with the closing to take place within 15 business days thereafter. The closing will be subject to the approval by the NYSE American of the Company's additional listing application and other customary closing conditions.

07:37 EDT Axsome Therapeutics announces anticipated milestones - Anticipated Milestones: NDA Submissions: AXS-05 in the treatment of MDD 4Q 2020; AXS-07 in the acute treatment of migraine 4Q 2020; FDA Meetings: AXS-05 for AD agitation 2H 2020; AXS-05 for smoking cessation 2H 2020; AXS-12 for narcolepsy 2H 2020; AXS-14 for fibromyalgia 2H 2020. Clinical Trial Readouts: Phase 2 COMET-TRD trial of AXS-05 in TRD, topline data 4Q 2020; Phase 2 COMET-AU trial of AXS-05 in antidepressant unresponsive MDD, topline data 4Q 2020; Phase 2 COMET-SI trial of AXS-05 in MDD with suicidal ideation, topline data 4Q 2020; Phase 2 MERIT trial of AXS-05 in TRD, topline data 1H 2021. Clinical Trial Initiations: Phase 3 trials of AXS-12 in narcolepsy 2H 2020; Phase 3 trial of AXS-05 in AD agitation 2H 2020.

07:34 EDT Precigen announces results from Phase 1b/2a study of AG019 ActoBiotics - Precigen ActoBio, a wholly-owned subsidiary of Precigen, announced it has met the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of early-onset type 1 diabetes, or T1D.The Phase 1b open-label portion of the study evaluates the safety and tolerability of AG019 administered as a single dose and repeated daily doses as a monotherapy in adult and adolescent patients. The primary endpoint for assessing safety and tolerability is treatment-emerging adverse events reported up to six months after treatment initiation. Nineteen patients were treated in the Phase 1b monotherapy portion of the study and 17 patients were evaluated at six months. The Phase 2a portion of the study is currently ongoing and investigates the safety and tolerability of AG019 in combination with teplizumab, which is currently under investigation in the PROTECT Phase 3 study for the treatment of newly diagnosed T1D.

07:33 EDT Momenta says Mylan expects U.S. submission for M710 in 2021 - Mylan continues its pivotal clinical trial in patients with diabetic macular edema to compare safety, efficacy and immunogenicity of M710 with EYLEA. Mylan expects to target U.S. submission in 2021, while monitoring and navigating potential COVID-19 issues.

07:32 EDT Cummins, Navistar announce new long-term agreement - Cummins (CMI) and Navistar International (NAV) said in a release, "Cummins and Navistar announced another step forward in their partnership by extending their long-term agreement through the next two emission cycles, with Cummins being selected as Navistar's preferred supplier of medium-duty and heavy-duty big bore engines for International Trucks and IC Buses in US and Canada. The Cummins B6.7 and L9 engines will continue to power the International MV and HV Series trucks, as well as Navistar's IC Bus CE and RE Series school busses."

07:31 EDT Momenta says CSL plans to introduce M230 Phase 1 program this year - Momenta's collaboration partner, CSL, plans to introduce a subcutaneous formulation into the Phase 1 program later this year.

07:30 EDT Momenta to initiate Phase 3 nipocalimab study in 1Q21 - In June 2020, Momenta announced positive topline data from an interim analysis of Vivacity-MG, the Company's Phase 2 study of nipocalimab in generalized myasthenia gravis. The results demonstrated that nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score at all doses and met the study's primary efficacy endpoint, demonstrating a linear and highly statistically significant relationship between Immunoglobulin G reduction and MG-ADL clinical benefit. Nipocalimab was also observed to be well-tolerated, with no adverse events leading to discontinuation. The study is expected to be completed in the third quarter of 2020, and the Company plans to present the full 16-week data in the fourth quarter of 2020. Additionally, Momenta has begun preparations to conduct an end of Phase 2 meeting with the U.S. Food and Drug Administration before the end of 2020 and anticipates initiating a Phase 3 study in the first quarter of 2021. Unity, Momenta's global multi-center Phase 2 clinical study of nipocalimab in hemolytic disease of the fetus and newborn, continues to enroll patients at sites where they can be safely accommodated. FDA recently granted Rare Pediatric Disease Designation and Orphan Drug Designation for nipocalimab in HDFN. Momenta continues to activate sites globally for the Energy Study, the Company's adaptive Phase 2/3 clinical study of nipocalimab in warm autoimmune hemolytic anemia. Patient enrollment was temporarily suspended due to the COVID-19 pandemic but is expected to resume in the fourth quarter 2020. Momenta has amended the study protocol to facilitate remote monitoring procedures.

07:27 EDT Chimerix announces expected upcoming milestones - Completion of NDA submission of BCV in third quarter 2020; Completion of enrollment of Phase 2 portion of DSTAT trial in COVID-19 in fourth quarter of 2020; Initiate Phase 3 AML trial in early 2021; Potential procurement agreement for BCV prior to FDA decision on smallpox NDA; FDA decision on BCV smallpox NDA in 2021; Completion of BCV drug product manufacturing to support a potential shipment to the SNS of up to $100 million in 2021

07:25 EDT Marriott expects COVID-19 'will continue to be material' to results - The company stated, "Due to the numerous uncertainties associated with COVID-19, Marriott cannot presently estimate the financial impact of this unprecedented situation, which is highly dependent on the severity and duration of the pandemic and its impacts, but expects that COVID-19 will continue to be material to the company's results."

07:23 EDT Phoenix New Media enters into share repurchase agreement with Run Liang - Phoenix New Media announced that it has entered into a new share purchase agreement with Run Liang Tai Management, which replaced the Company's previous agreement with Run Liang Tai for the sale of the Company's investment in Particle to Run Liang Tai and its designated entities. As previously announced by the Company, the Company has completed delivery of the first batch of Particle shares to the Proposed Buyers and received consideration of $200M for such shares as well as a further deposit of $50M pursuant the Previous Agreement, and the Proposed Buyers was required to pay the remaining purchase price for the second batch of Particle shares to the Company on or before August 10 under the Previous Agreement. The rights and obligations of both the Proposed Buyers and the Company with respect to the second batch of shares under the Previous Agreement were terminated pursuant to the New SPA, and instead, the Company agreed to sell a total of 140,248,775 shares of Particle, representing all of the Particle shares the Company currently holds, to the Proposed Buyers at a total purchase price of $150M. The Proposed Buyers has paid approximately $99.3M to the Company under the New SPA, which represents the difference between the total purchase price and the $50M deposit already paid by the Proposed Buyers under the Previous Agreement plus certain other accrued interests. The Company will be required to deliver the 140,248,775 shares of Particle to the Proposed Buyers after certain closing conditions are satisfied.

07:21 EDT TG Therapeutics announces key objectives for 2020, early 2021 - Report topline results from the Phase 3 ULTIMATE I & II trials in Multiple Sclerosis. Present full data from the UNITY-CLL Phase 3 trial and present full data from the FL and MZL single agent umbralisib cohorts of the UNITY-NHL trial at a major medical meeting. Target an NDA/Biologics Licensing Application submission of U2 for the treatment of patients with CLL. Continue to advance our early pipeline candidates including our anti-PD-L1 monoclonal antibody, cosibelimab, our Bruton's Tyrosine Kinase inhibitor, TG-1701, and our anti-CD47/CD19 bispecific antibody, TG-1801.

07:18 EDT Townsquare expects Interactive business to generate $100M in two years - The company said, "Townsquare Interactive's growth continued in the Q2, with net revenue increasing 10.5%, at an Adjusted Operating Income margin in excess of 30%, and approximately 900 net subscriber additions, marking the 9th consecutive quarter of 850 or more net subscriber additions. During this pandemic, the Townsquare Interactive team became a tremendous resource for their local clients by strengthening their online presence and capabilities and powering their online communication strategy. We believe, and our thesis has always been, that Townsquare Interactive is a recession-resistant subscription business and will continue to grow its revenue and subscriber base throughout the year. We remain confident that Townsquare Interactive will each generate $100M of annual net revenue in two to four years."

07:18 EDT Axsome Therapeutics completes enrollment in COMET Phase 3 study of AXS-05 - Axsome Therapeutics announces continued progress toward NDA filing of AXS-05 in the treatment of major depressive disorder, and the generation of new clinical data to further characterize the antidepressant profile of AXS-05 across a broad spectrum of patients with MDD. Enrollment has been completed in the COMET Phase 3 open-label, long-term safety trial to support the planned NDA filing of AXS-05 in MDD. In addition, the required number of patients treated for 6 months has been reached. Filing of the NDA remains on track for the fourth quarter of 2020. Axsome is also conducting three Phase 2 open-label efficacy sub-studies of the COMET trial which will evaluate the efficacy and safety of AXS-05 in three clinically pertinent MDD patient populations: the COMET-TRD trial in treatment resistant MDD, the COMET-AU trial in antidepressant unresponsive MDD, and the COMET-SI trial in MDD with suicidal ideation. Efficacy results from these studies are expected in the fourth quarter of 2020. Further, Axsome has initiated the MERIT trial, a Phase 2, double-blind, placebo-controlled, randomized withdrawal study in patients with TRD. Results from the MERIT trial, which are expected in the first half of 2021, along with results from the COMET-TRD trial, which are expected in the fourth quarter of 2020, will provide clinically useful information with AXS-05 in this treatment resistant MDD population. Enrollment has been completed in the COMET Phase 3, open-label, long-term safety trial of AXS-05 to support the New Drug Application filing in MDD. Nearly 900 patients have been enrolled, of whom more than 500 have been treated for at least 6 months to date. At least 300 patients treated for 6 months and 100 patients treated for one year are required for the NDA filing. Axsome remains on track to achieve the required number of patients treated for one year in the fourth quarter. Axsome previously announced that it had completed a pre-NDA meeting for AXS-05 in MDD with the U.S. Food and Drug Administration to reach agreement on the proposed content and format of the Company's planned NDA submission, including the clinical and nonclinical requirements. Based on the feedback from the FDA, the Company believes its regulatory data package will be sufficient to support an NDA for AXS-05 in MDD, and Axsome remains on track to submit the planned NDA in the fourth quarter of 2020. COMET-TRD Trial - Axsome is conducting the COMET-TRD trial, a Phase 2 open-label sub-study evaluating the efficacy and safety of AXS-05 in TRD patients. The trial will include approximately 70 patients who have had ongoing symptoms of depression despite receiving treatment with two or more prior antidepressants during the current major depressive episode. The trial endpoints will include the change from baseline in the Montgomery-Asberg Depression Rating Scale total score, clinical response, and remission. Topline results from the COMET-TRD trial are expected in the fourth quarter of 2020. MERIT Trial - Axsome is conducting the MERIT trial, a Phase 2, double-blind, placebo-controlled, randomized withdrawal study of AXS-05 in patients with TRD. The trial will include approximately 50 patients who have had ongoing symptoms of depression despite receiving treatment with two or more prior antidepressants during the current major depressive episode. In this trial, patients who experience a sustained remission of depressive symptoms after treatment with open-label AXS-05 will be randomized to continued treatment with AXS-05 or to placebo in a double-blind fashion. The primary endpoint of the trial is the time to relapse of depressive symptoms. Topline results from the MERIT trial are expected in the first half of 2021. The MERIT and COMET-TRD trials are being conducted in lieu of the previously planned Phase 3 trial in TRD. This approach will more quickly generate clinically useful information with AXS-05 in this treatment resistant MDD population, starting as early as the fourth quarter of 2020. COMET-AU Trial - Axsome is conducting the COMET-AU trial, a Phase 2 open-label sub-study evaluating the efficacy and safety of AXS-05 in patients with antidepressant unresponsive MDD. The trial will include approximately 150 patients with ongoing symptoms of depression despite receiving one standard antidepressant pharmacotherapy. The trial endpoints will include the change from baseline in the MADRS total score, clinical response, and remission. Topline results from the COMET-AU trial are expected in the fourth quarter of 2020. COMET-SI Trial - Axsome is conducting the COMET-SI trial, a Phase 2 open-label sub-study evaluating the efficacy and safety of AXS-05 in MDD patients with suicidal ideation. The trial will include approximately 30 patients. The trial endpoints will include the resolution of suicidal ideation. Topline results from the COMET-SI trial are expected in the fourth quarter of 2020.

07:16 EDT Marriott added more than 11,400 rooms globally during Q2 - The company added more than 11,400 rooms globally during the second quarter, including roughly 2,000 rooms converted from competitor brands and approximately 4,700 rooms in international markets. Net rooms grew 4.1 percent from a year ago. At quarter-end, Marriott's worldwide development pipeline totaled nearly 3,000 hotels and approximately 510,000 rooms, including roughly 28,000 rooms approved, but not yet subject to signed contracts. Over 230,000 rooms in the pipeline were under construction as of the end of the second quarter.

07:15 EDT NantKwest, CBR by Generate Life Sciences announce collaboration - CBR by Generate Life Sciences and NantKwest announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio. The partnership kicks off immediately, with patient trials expected to begin in the Fall. Both companies anticipate an FDA approved treatment to be in the market for use in COVID-19 patients by early 2021.

07:11 EDT Voyager Therapeutics announces anticipated upcoming milestones - VY-AADC for Parkinson's Disease: Report 3-year results from PD-1101 trial September 2020; Report 2-year results from PD-1102 trial -September 2020; Resume patient screening and enrollment in RESTORE-1 Phase 2 clinical trial 2H 2020 Initiate RESTORE-2 Phase 3 registrational clinical trial 1H 2020. VY-HTT01 for Huntington's Disease: IND application and Phase 1 trial initiation update post-FDA clearance; Present IND-enabling preclinical results at a scientific congress 1H 2021. Early Pipeline and Platform: Provide progress updates on earlier-stage research programs, including novel capsid discovery efforts

07:08 EDT DouYu receives proposal letter from Tencent for merger with Huya - DouYu International Holdings announced that its Board of Directors has received a preliminary non-binding proposal letter, dated August 10 from Tencent Holdings Limited, proposing that DouYu and HUYA enter into a stock-for-stock merger, as a result of which Huya or its subsidiary would acquire each outstanding ordinary share of DouYu. Pursuant to the Proposed Transaction, shareholders of DouYu will receive a to be agreed number of newly issued Class A ordinary shares of Huya for their respective DouYu shares. A copy of the proposal letter is attached hereto as Exhibit A. The Board plans to review and evaluate the Proposed Transaction. The Board cautions the Company's shareholders and others considering trading the Company's securities that the Board has just received the proposal letter and has not had an opportunity to carefully review and evaluate the Proposed Transaction or make any decision with respect to the Company's response to the Proposed Transaction.

07:07 EDT Bruker supports international COVID-19-NMR consortium - Bruker announced its support of a worldwide collaborative project that investigates the structures, dynamics, function and binding of SARS-CoV-2 viral RNA and proteins using high-field nuclear magnetic resonance, or NMR, spectroscopy. The COVID-19-NMR consortium was initiated at Goethe University, or GU, in Frankfurt, Germany, and leverages the extensive experience of the GU Biological Magnetic Resonance Center and of 30 consortium groups in 15 countries in high-field NMR, structural biology, and small molecule drug screening. The company said, "The fight against the global COVID-19 pandemic is one of the greatest challenges currently facing mankind. The international Covid19-NMR consortium aims to determine the dynamics, function and potential for therapeutic intervention of the ribonucleic acid (RNA) and protein structures of SARS-CoV-2, with a focus on investigating the potential of small molecule drugs to bind to these viral biopolymer structures. The results are made publicly available prior to publication in order to communicate progress quickly and to a wide research network."

07:03 EDT Marriott expects COVID-19 to 'will continue to be material' to results - The company stated, "Due to the numerous uncertainties associated with COVID-19, Marriott cannot presently estimate the financial impact of this unprecedented situation, which is highly dependent on the severity and duration of the pandemic and its impacts, but expects that COVID-19 will continue to be material to the company's results."

07:01 EDT Marriott reports Q2 comparable systemwide constant dollar RevPAR down 84.4% - Q2 comparable systemwide constant dollar RevPAR declined 84.4% worldwide, 83.6% in North America and 86.7% outside North America.

07:00 EDT Mallinckrodt announces FDA filing acceptance of BLA for StrataGraft - Mallinckrodt said in a release, "The FDA has accepted for review the Stratatech Biologics License Application, or BLA, for StrataGraft, an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The FDA granted the application priority review and assigned a Prescription Drug User Fee Act target date of February 2, 2021."

06:55 EDT Pieris Pharmaceuticals, Eli Lilly enter into clinical trial collaboration - Pieris Pharmaceuticals said in a release, "Pieris Pharmaceuticals (PIRS) announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a VEGFR2 antagonist FDA-approved for multiple types of solid tumors, and paclitaxel for the second-line treatment of patients with HER2-positive gastric cancer in a phase 2 study. Under the terms of the agreement, Lilly will supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year."

06:52 EDT Foot Locker reports Q2 SSS up 18%

06:50 EDT Reata Pharmaceuticals says pre-NDA meeting granted for Bardoxolone - The company said, "Since the announcement of positive, Year 1 data from the Phase 3 CARDINAL study, we have been engaged in discussions with the U.S. FDA regarding the Year 1 efficacy and safety results. We have had a Type C meeting and have provided written responses to the FDA's questions and comments. We believe that we have addressed the FDA's questions and comments regarding the Year 1 results, and, accordingly, we recently requested and were granted a pre-NDA meeting by the FDA to discuss the NDA submission content and plans. One of the key questions to be resolved in the pre-NDA meeting is how the data from Year 2 of the CARDINAL study should be handled during the NDA review process. Our plan has been, and continues to be, to submit the NDA for bardoxolone in Alport syndrome during fourth quarter of 2020 for accelerated approval based on the one-year data from the Phase 3 portion of CARDINAL. If the second-year results are available during an acceptable time frame, we may be able to submit the second-year data to the NDA during the review process and before the FDA makes a determination about accelerated approval. This may extend the PDUFA date, but could also result in consideration of full approval, rather than accelerated approval. The FDA could recommend that we wait for the second-year data from CARDINAL to file the NDA. This would permit us to file for full approval but would delay the filing until the first quarter of 2021, compared to our current guidance of filing by the end of this year."

06:41 EDT LogicBio Therapeutics announces clinical trial design for LB-001 - LogicBio Therapeutics announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia, or MMA. The SUNRISE trial is a multi-center, open-label, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with MMA characterized by methylmalonyl-CoA mutase gene, or MMUT, mutations. Six leading centers in the United States are expected to participate in the SUNRISE Phase 1/2 trial. The trial is expected to enroll eight pediatric patients with ages ranging from 6 months to 12 years, initially starting with 3 to 12 year-old patients and then adding patients aged 6 months to 2 years. The SUNRISE Phase 1/2 trial will evaluate two doses of LB-001. Patients will participate in a pre-dosing observational period and will be administered a prophylactic steroid regimen. The primary endpoint of the SUNRISE trial is to assess the safety and tolerability of LB-001 at 52 weeks after a single infusion. Additional endpoints include changes in disease-related biomarkers, including serum methylmalonic acid, clinical outcomes such as growth and healthcare utilization, and the pharmacodynamic marker albumin-2A. The Company expects to enroll the first patient in early 2021.

06:38 EDT InspireMD regains NYSE American compliance - InspireMD announced that as of August 7, the company has regained compliance with the NYSE American's continued listing standards.

06:37 EDT Pieris Pharmaceuticals, Eli Lilly enter clinical trial collaboration - Pieris Pharmaceuticals (PIRS) announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a VEGFR2 antagonist FDA-approved for multiple types of solid tumors, and paclitaxel for the second-line treatment of patients with HER2-positive gastric cancer in a phase 2 study. Under the terms of the agreement, Lilly will supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year.

06:32 EDT Seres Therapeutics reports 'positive' results from Phase 3 ECOSPOR III study - Seres Therapeutics reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection. The study showed that SER-109 administration resulted in a highly statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a recurrence in CDI within eight weeks of administration versus placebo, the study's primary endpoint. 11.1% of patients administered SER-109 experienced a CDI recurrence, versus 41.3% of placebo patients. The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study's efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. FDA that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application. The SER-109 safety results were favorable, with an adverse event profile comparable to placebo.

06:15 EDT Barrick Gold says 'on track' to achieve 2020 annual production guidance - At the year's halfway mark, Barrick Gold was on track to achieve annual production within its 2020 guidance range, despite the impact of the Covid-19 pandemic, the company said. Second quarter results show year-to-date gold production of 2.4M ounces, at the mid-point of its 4.6M-5M ounce annual guidance, driven by strong operating performances, particularly from Nevada Gold Mines in the United States, Loulo-Gounkoto in Mali and Kibali in the Democratic Republic of Congo. Barrick's copper portfolio continued to outperform with Lumwana in Zambia posting its best quarterly production in years.

06:08 EDT Georgia Power, Cox Automotive Mobility complete EV charging installation - Cox Automotive Mobility's Pivet Atlanta facility, located between downtown Atlanta and Hartsfield-Jackson Atlanta International Airport, completed one of the largest electric vehicle, or EV, charging single property installations in the southeast in collaboration with Georgia Power and EV charging network provider ChargePoint. The Smart Technology Project, which includes the installation of 20 Level 2 fleet chargers, six fleet DC Fast Chargers and six public DC Fast Chargers, fills a need for charging access in South Metro Atlanta, an area that has historically been an EV charging desert. The design and build of the installation delivered by Georgia Power's Utility Services is intended to primarily support fleet electrification, including but not limited to powering the Lyft Express Drive program currently operated out of Pivet Atlanta. The facility will also serve other fleets and OEMs in search of a charging solution on the city's south side. The charging stations manufactured by ChargePoint have been set up on a time-of-use rate to provide low cost of fueling during off-peak hours. In addition, through ChargePoint's vertically integrated cloud network services, Pivet Atlanta will be able to monitor and collect detailed data on charging sessions and station usage, helping gain a more comprehensive view of the charging needs and requirements of the users. This will also help track the need for further growth. In addition to handling today's charging needs, capacity has been built into Georgia Power's electric design for the anticipated EV expansion in the coming years. This includes the installation of DC Fast Chargers that can be combined to provide 125kW high-output charging for the larger batteries of the future. Parking spaces at the Pivet Atlanta facility have also been designed to accommodate larger commercial fleet vehicles, such as electric delivery vans and trucks.

06:04 EDT RadNet is evaluating the re-opening of locations - The company commented, "We will continue to evaluate the re-opening of locations and bring back furloughed employees as our business further recovers. Currently, 25 of our 332 facilities remain closed. During the COVID-19 period, we were assisted by approximately $25.5Min grants we received under the CARES Act Provider Relief Fund and approximately $44.4M we received in the form of advances from the Centers for Medicare and Medicaid Services and one west coast insurance company. Despite having to repay these advances during the second half of this year, we expect that our business will add to the $84.6M cash balance we had at quarter end."

05:58 EDT Canadian Natural acquires Painted Pony Energy for C$350M - Canadian Natural said in a release, "Canadian Natural Resources announces it has entered into a definitive arrangement agreement with Painted Pony Energy relating to the acquisition of all the issued and outstanding common shares of Painted Pony, for a cash consideration of C$0.69 per share. The Company will also assume Painted Pony's total debt of approximately C$350 million. This transaction value represents approximately 1% of Canadian Natural's enterprise value and does not materially impact the Company's balance sheet strength or liquidity position. Painted Pony's land and production are located within Canadian Natural's core area providing opportunity to leverage synergies with a significant amount of pre-built infrastructure and transportation available. Current production, before royalties, acquired by Canadian Natural, is approximately 270 million cubic feet per day of natural gas and 4,600 barrels per day of NGLs. The assets include properties in the Northeast British Columbia areas of Blair, Daiber, Kobes and Townsend."

05:55 EDT Opera announces new partnership with Google My Business - Opera (OPRA) said in a release, "Opera is extending its offering to help small and medium enterprises, or SMEs, in Nigeria to become easily discoverable online by announcing the launch of its new service Opera For Business. With Opera For Business SMEs can create an online profile of their business, tell their story to their customers online, and show accurate location as well as opening hours across Google's (GOOG, GOOGL) popular services such as Google Maps. The new offering of Opera also features a rich set of digital marketing and advertising services that will enable business owners to promote their enterprise to new and potential customers across the country. Opera is also extending its value proposition in Nigeria by partnering with Google My Business, a tool that helps businesses and organizations manage their online presence across Google properties, including Google Search and Google Maps."

05:39 EDT TSMC reports July revenue NT$105.96B, up 25% y/y - TSMC announced its net revenues for July 2020: On a consolidated basis, revenues for July 2020 were approximately NT$105.96B, a decrease of 12.3% from June 2020 and an increase of 25% from July 2019. Revenues for January through July 2020 totaled NT$727.26B, an increase of 33.6% compared to the same period in 2019.

05:14 EDT Genentech says etrolizumab trial met one primary endpoint, failed to meet other - Genentech, a member of the Roche Group, announced topline results from its Phase III study program evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Genentech said in a release, "Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumor necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. In contrast, the HIBISCUS II induction study, which also included people without prior anti-TNF treatment, did not meet its primary endpoint. In the HICKORY study, in people with prior anti-TNF treatment, etrolizumab met the primary endpoint at induction but not at maintenance. In the LAUREL maintenance study in people without prior anti-TNF treatment, etrolizumab failed to meet its primary endpoint. The safety profile of etrolizumab was consistent with previous studies and no major safety issues were identified in the four Phase III clinical trials reported to date. Further analyses of the data, including secondary endpoints, are ongoing and will be submitted for presentation at upcoming medical meetings. Etrolizumab continues to be studied as an investigational induction and maintenance treatment in people with moderately to severely active Crohn's disease with and without prior anti-TNF treatment in a global Phase III study (BERGAMOT) and open-label extension and safety monitoring study (JUNIPER), involving more than 1,100 people with Crohn's disease. In addition, Genentech is studying other investigational medicines in inflammatory bowel diseases and is committed to further understanding this disease."